Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|November 11, 2020
Optibrium, MSD Enter Cheminformatics Collaboration
Author(s)Pharmaceutical Technology Editors
Optibrium has entered into a cheminformatics collaboration with MSD (known as Merck & Co. in the United States).
Advertisement
Drug discovery software developer, Optibrium, has entered into a collaboration with MSD (known as Merck & Co. in the United States) for the integration of Optibrium’s software into MSD’s drug discovery infrastructure.
According to a Nov. 10, 2020 press release, the agreement covers the integration of Optibrium’s StarDrop software as a central component of MSD’s cheminformatics infrastructure. The resultant combination of Optibrium’s software with MSD’s in-house capabilities is expected to improve cycle times, efficiency, and productivity of drug discovery.
“We are delighted to enter this collaboration to contribute to MSD’s world-leading cheminformatics infrastructure,” said Dr. Matthew Segall, Optibrium’s CEO, in the press release. “We look forward to working together to advance new tools based around StarDrop to further refine our compound design platform.”
Source:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
Can Continuous Tableting End Scale-Up for Complex Oral Drugs?
5